GGrantIndex
← Leaderboards

Scott Michael Damrauer

University Of Pennsylvania

$2,419,569
Attributed
$3,401,632
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY201825
$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,401,632 · 3
VA$0 · 2

By mechanism

R01$3,401,632 · 3
I01$0 · 1
IK2$0 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Genome Wide Association Study

Research focus

Genome Wide Association StudyGeneticPreventAffectPharmaceutical PreparationsGenomicsPrecision MedicineHeartRisk FactorsLipidsCessation Of LifeTraitBlood PressureCardiovascular Disorder RiskCerebrovascular DisordersIschemic StrokeMorbidity - Disease RateArteriesCardiovascular DiseasesElectronic Health RecordGenetic RiskHigh RiskDesignAlgorithms

Grant awards (14)

MTSS1 in myocardial disease$759,712
R01 · FY2025 · HL
Triglyceride-rich lipoproteins and abdominal aortic aneurysm growth and progression$713,382
R01 · FY2025 · HL · contact PI
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth$675,678
R01 · FY2025 · HL · contact PI
Leveraging the Genetics of carotid stenosis for identifying novel risk factors and therapeutic opportunities$0
I01 · FY2025 · VA · contact PI
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth$589,331
R01 · FY2024 · HL · contact PI
Leveraging the Genetics of carotid stenosis for identifying novel risk factors and therapeutic opportunities$0
I01 · FY2024 · VA · contact PI
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth$663,529
R01 · FY2023 · HL · contact PI
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk Prediction$0
IK2 · FY2023 · VA · contact PI
Leveraging the Genetics of carotid stenosis for identifying novel risk factors and therapeutic opportunities$0
I01 · FY2023 · VA · contact PI
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk Prediction$0
IK2 · FY2022 · VA · contact PI
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk Prediction$0
IK2 · FY2021 · VA · contact PI
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk Prediction$0
IK2 · FY2020 · VA · contact PI
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk Prediction$0
IK2 · FY2019 · VA · contact PI
Precision Cardio-Metabolic Phenotyping for Genetic Discovery and Risk Prediction$0
IK2 · FY2018 · VA · contact PI